PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29665663-0	2018	[Analysis of neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) in HER-2-positive breast cancer].	thiocarbohydrazide	65-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	73-78	
29665663-3	2018	The data of patients with HER-2 positive conducted TCH neoadjuvant therapy and surgery, and with the complete clinicopathological information were analyzed.	thiocarbohydrazide	51-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	26-31	
29665663-9	2018	Conclusion: TCH is an effective neoadjuvant therapy for patients with HER-2 positive breast cancer, and the toxic and side effects were under control.	thiocarbohydrazide	12-15	erb-b2 receptor tyrosine kinase 2	Homo sapiens	70-75